Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Revenue: 2009-2025

Historic Revenue for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $227.8 million.

  • Ani Pharmaceuticals' Revenue rose 53.58% to $227.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $826.9 million, marking a year-over-year increase of 48.87%. This contributed to the annual value of $614.4 million for FY2024, which is 26.20% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Revenue stood at $227.8 million for Q3 2025, which was up 7.78% from $211.4 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Revenue's 5-year high stood at $227.8 million during Q3 2025, with a 5-year trough of $11.2 million in Q1 2021.
  • Moreover, its 3-year median value for Revenue was $138.0 million (2024), whereas its average is $158.0 million.
  • In the last 5 years, Ani Pharmaceuticals' Revenue plummeted by 77.50% in 2021 and then surged by 475.69% in 2022.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Revenue stood at $60.9 million in 2021, then skyrocketed by 54.66% to $94.2 million in 2022, then soared by 39.71% to $131.7 million in 2023, then soared by 44.75% to $190.6 million in 2024, then soared by 53.58% to $227.8 million in 2025.
  • Its last three reported values are $227.8 million in Q3 2025, $211.4 million for Q2 2025, and $197.1 million during Q1 2025.